Adjunctive Hemostats Market

The global adjunctive hemostats market was valued at USD 2.02 Bn in 2025 and is estimated at USD 2.14 Bn in 2026. The market is projected to reach USD 3.40 Bn by 2034, representing a 6.0% CAGR during 2026–2034.

Adjunctive hemostats are used when conventional bleeding-control methods such as sutures, cautery or ligation are impractical, ineffective or insufficient. The market spans passive absorbable materials, powders, gelatin sponges and active flowable products, with product choice influenced by bleeding severity, anatomy, surgeon preference, preparation time, absorption profile and hospital contracting.

Current product portfolios illustrate a broad technology spectrum. Ethicon lists SURGICEL Powder as a 3.0 g oxidized regenerated cellulose product with a 7–14 day absorption time, while Baxter positions FLOSEAL with recombinant thrombin as an active flowable hemostat that can achieve hemostasis in as little as 60 seconds. These differences create distinct use cases and pricing tiers rather than one homogeneous product category.

Commercial demand is tied to surgical volume, complexity and operating-room efficiency. Hospitals value products that can control diffuse or difficult-to-access bleeding without adding unnecessary preparation steps, but premium products must demonstrate enough workflow or clinical benefit to justify higher acquisition costs and training requirements.

Source: Ethicon SURGICEL Powder; Baxter FLOSEAL; FDA SURGICEL Powder S129.

The study covers adjunctive hemostatic materials used in surgical and procedural bleeding control, with analysis by product type, care setting and geography.

Complex surgical bleeding sustains need for adjunctive products

Surgeons frequently need localized hemostatic support when capillary, venous or small-arterial bleeding cannot be controlled efficiently with ligation or standard techniques. Ethicon’s SURGICEL Powder indication directly reflects this use case, supporting a broad procedure base for adjunctive materials.

Speed and preparation affect operating-room economics

Baxter states FLOSEAL can achieve hemostasis in as little as 60 seconds. In time-sensitive surgery, preparation and application speed can influence product preference because delays affect room utilization and staff workflow.

Material platform determines clinical fit

Oxidized regenerated cellulose, gelatin, powders and active thrombin-containing matrices behave differently in wet fields, irregular surfaces and varying bleeding grades. This makes portfolio breadth commercially valuable because hospitals prefer suppliers that can cover multiple surgical scenarios.

Premium acquisition cost creates procurement pressure

Advanced flowable and active products can carry higher per-unit costs than traditional passive materials. Value committees therefore assess evidence, waste, preparation, training and procedure-specific benefit before expanding formulary access.

Powder formats improve coverage of broad or irregular surfaces

Powders can conform to diffuse bleeding areas and difficult anatomy without requiring precise cutting or shaping. This handling advantage supports adoption where traditional gauze or sponge placement is cumbersome.

Recombinant components reduce reliance on human blood sourcing

Baxter’s FLOSEAL with RECOTHROM uses recombinant thrombin and contains no human blood components. Recombinant sourcing provides a differentiated safety and supply narrative within active hemostasis.

Lifecycle engineering supports product continuity

FDA supplements for SURGICEL Powder in 2024 and 2026 covered specification, shelf-life, manufacturing and material-supplier changes. These updates show that mature hemostat platforms continue to receive manufacturing and design investment rather than remaining static products.

Emerging-market surgical capacity expands volume opportunity

Hospital expansion and rising surgical access in Asia-Pacific, Latin America and the Middle East create new demand for both cost-efficient passive products and premium adjuncts in advanced centers. Local distribution and pricing are decisive for market conversion.

Passive absorbable matrices provide broad baseline utility

Gauze, cellulose and gelatin products create a physical matrix that supports clot formation and can be applied across many surgical specialties. Their familiarity, storage simplicity and range of shapes sustain a broad installed demand base.

Powders increase conformability

Powdered hemostats can cover complex or irregular surfaces and may be deployed where sheet or sponge formats are less practical. Applicator design and powder distribution become key product-differentiation points.

Active flowables add biological hemostatic action

Products containing thrombin combine a physical matrix with active clotting support. They can command higher value in more demanding bleeds, but preparation, contraindications, training and acquisition cost influence adoption.

Gauze

Gauze and sheet-like absorbable hemostats hold a broad procedure base because they are familiar, versatile and available across multiple sizes and materials. Demand is supported by general surgery and specialty procedures where direct placement is practical.

Powder

Powder products are gaining strategic importance because they can cover broad, irregular or difficult-to-reach bleeding surfaces. Their commercial value is tied to rapid deployment, applicator design and the ability to conform without shaping.

Gelatin Sponge

Gelatin sponges remain established in surgical hemostasis due to absorbability, compressibility and familiarity across specialties. They compete on handling, size range, absorption characteristics and compatibility with thrombin or other adjuncts.

Other

Other adjunctive products include flowable matrices, combination technologies and specialty materials designed for specific bleeding grades or anatomies. These segments often carry higher unit value and stronger evidence requirements.

The type mix is expected to shift gradually toward powders, flowables and differentiated combination products, while gauze and gelatin formats retain substantial volume due to familiarity and cost effectiveness.

Hospital

Hospitals represent the largest application base because they perform complex surgery across cardiovascular, orthopedic, general, neuro, transplant and other specialties. Formularies, value-analysis committees and system contracts strongly influence vendor share.

Clinics

Clinics and ambulatory procedure settings use adjunctive hemostats in selected surgeries where rapid bleeding control and compact product handling are valuable. Adoption depends on procedure mix, reimbursement and inventory economics.

Others

Other users include ambulatory surgery centers, specialty surgical centers, emergency settings and institutional care environments where localized bleeding control is required outside traditional inpatient operating rooms.

Hospital procurement will remain the main revenue base, while outpatient surgical growth creates incremental opportunities for compact, easy-to-use formats.

Regional demand reflects surgical volume, hospital technology adoption, reimbursement, procurement practices and local availability of both premium and value hemostatic products. Country spotlights are limited to markets where regulatory or product-access evidence adds clear commercial context.

FDA supplements demonstrate active lifecycle management

SURGICEL Powder received FDA supplement decisions in December 2024 and July 2026 covering specification, shelf-life and material-related changes. Mature surgical products still require ongoing regulatory control as manufacturing and components evolve.

Hospital value analysis shapes adoption

Large health systems evaluate hemostats through clinical evidence, surgeon preference, contracting, standardization and total procedure economics. Winning formulary placement can create recurring volume across many specialties, while losing a system contract can materially reduce share.

Training and correct application influence real-world value

Adjunctive hemostats are not interchangeable in every bleeding situation. Product-specific preparation, placement and contraindications mean suppliers often support in-service education, which becomes part of the commercial relationship and switching cost.

Competition spans global surgical-products companies and regional hemostat manufacturers. Portfolio breadth is strategically important because hospitals prefer suppliers that can address passive, powder, sponge and flowable use cases while supporting contracting, training and inventory simplification.

Future share gains are likely to favor suppliers that combine clinically useful product differentiation with strong evidence, reliable manufacturing, practical preparation and hospital-contracting reach.

• Johnson & Johnson
• BD
• Baxter
• B. Braun
• Cura Medical
• GELITA MEDICAL
• Curasan AG
• Meril Life Sciences
• Zhonghui Shengxi
• Beijing Datsing Bio-tech
• Guizhou Jin Jiu Biotech
• Beijing Taikesiman
• Foryou Medical
• Saikesaisi Holdings Group
• Biotemed

The global adjunctive hemostats market market is estimated at USD 2.14 Bn in 2026 and is projected to reach USD 3.40 Bn by 2034, representing a 6.0% CAGR during 2026–2034.

The Adjunctive Hemostats Market study is structured to support market sizing, segment planning, competitive assessment and geographic prioritization without exposing the detailed paid databook in the public overview.

Market sizing uses top-down reconciliation of addressable procedure, treatment or equipment pools with bottom-up company, product, channel and geography checks. Primary and secondary research are triangulated to test market boundaries, segment relationships and forecast assumptions.

Secondary research prioritizes regulators, government agencies, clinical or professional authorities, peer-reviewed literature, company filings and official product documentation. Company revenue is used only when it can be related to the target market without assigning unrelated portfolio sales to the market.

Forecasting considers adoption, replacement cycles, pricing, reimbursement, regulatory change, clinical practice, installed-base dynamics, competitive launches and geographic access. For surgical consumables, procedure mix, product format, hospital formularies, contracting, price tiers, technology substitution and regional surgical capacity are considered alongside company portfolio and regulatory evidence.